{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:10:43Z","timestamp":1788282643490,"version":"build-2803163510"},"reference-count":39,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,7,1]]},"abstract":"<jats:p>Objective. Some children in the United States continue to be exposed to levels of lead that increase their risk for lowered intellectual functioning and behavior problems. It is unclear whether chelation therapy can prevent or reverse the neurodevelopmental sequelae of lead toxicity. The objective of this study was to determine whether chelation therapy with succimer (dimercaptosuccinic acid) in children with referral blood lead levels between 20 and 44 \u03bcg\/dL (0.96-2.12 \u03bcmol\/L) at 12 to 33 months of age has neurodevelopmental benefits at age 7 years.<\/jats:p>\n               <jats:p>Methods. The Treatment of Lead-Exposed Children (TLC) study is a randomized, double-blind, placebo-controlled trial that was conducted between September 1994 and June 2003 in Philadelphia, PA; Newark, NJ; Cincinnati, OH; and Baltimore, MD. Of 1854 referred children who were between the ages of 12 to 33 months and screened for eligibility, 780 were randomized to the active drug and placebo groups stratified by clinical center, body surface area, blood lead level, and language spoken at home. At 7 years of age, 647 subjects remained in the study. Participants were randomly assigned to receive oral succimer or placebo. Up to 3 26-day courses of succimer or placebo therapy were administered depending on response to treatment in those who were given active drug. Eighty-nine percent had finished treatment by 6 months, with all children finishing by 13 months after randomization. All participants received residential lead hazard control measures before treatment. TLC subjects also received a daily multivitamin supplement before and after treatment(s) with succimer or placebo. Scores on standardized neuropsychological measures that tap cognition, behavior, learning and memory, attention, and neuromotor skills were measured.<\/jats:p>\n               <jats:p>Results. Chelation therapy with succimer lowered average blood lead levels for \u223c6 months but resulted in no benefit in cognitive, behavioral, and neuromotor endpoints.<\/jats:p>\n               <jats:p>Conclusion. These new follow-up data confirm our previous finding that the TLC regimen of chelation therapy is not associated with neurodevelopmental benefits in children with blood lead levels between 20 and 44 \u03bcg\/dL (0.96\u20132.17 \u03bcmol\/L). These results emphasize the importance of taking environmental measures to prevent exposure to lead. Chelation therapy with succimer cannot be recommended for children with blood lead levels between 20 and 44 \u03bcg\/dL (0.96\u20132.12 \u03bcmol\/L).<\/jats:p>","DOI":"10.1542\/peds.114.1.19","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:53:04Z","timestamp":1092444784000},"page":"19-26","source":"Crossref","is-referenced-by-count":157,"title":["Effect of Chelation Therapy on the Neuropsychological and Behavioral Development of Lead-Exposed Children After School Entry"],"prefix":"10.1542","volume":"114","author":[{"given":"Kim N.","family":"Dietrich","sequence":"first","affiliation":[{"name":"University of Cincinnati College of Medicine, Department of Environmental Health, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Ware","sequence":"additional","affiliation":[{"name":"Harvard University, School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Salganik","sequence":"additional","affiliation":[{"name":"Harvard University, School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerilynn","family":"Radcliffe","sequence":"additional","affiliation":[{"name":"Children's Hospital of Philadelphia, Department of Psychology, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter J.","family":"Rogan","sequence":"additional","affiliation":[{"name":"National Institute of Environmental Health Sciences, Epidemiology Branch, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G.","family":"Rhoads","sequence":"additional","affiliation":[{"name":"University of Medicine and Dentistry of New Jersey, Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey #Kennedy Krieger Institute, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha E.","family":"Fay","sequence":"additional","affiliation":[{"name":"Harvard University, School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia T.","family":"Davoli","sequence":"additional","affiliation":[{"name":"University of Medicine and Dentistry of New Jersey, Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey #Kennedy Krieger Institute, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha B.","family":"Denckla","sequence":"additional","affiliation":[{"name":"University of Medicine and Dentistry of New Jersey, Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey #Kennedy Krieger Institute, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Bornschein","sequence":"additional","affiliation":[{"name":"University of Cincinnati College of Medicine, Department of Environmental Health, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Children's Hospital of Philadelphia, Department of Adolescent Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Dockery","sequence":"additional","affiliation":[{"name":"Harvard University, School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Adubato","sequence":"additional","affiliation":[{"name":"University of Medicine and Dentistry of New Jersey, Department of Pediatrics, Newark, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Jones","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Nutritional Biochemistry Branch, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Treatment of Lead-Exposed Children Clinical Trial Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2004,7,1]]},"reference":[{"key":"2021121006511282800_R1","doi-asserted-by":"crossref","unstructured":"Christian JR, Celewycz BS, Andelman SH. A three-year study of lead poisoning in Chicago. Am J Public Health.\u20081964;54:1241\u20131245","DOI":"10.2105\/AJPH.54.8.1241"},{"key":"2021121006511282800_R2","doi-asserted-by":"crossref","unstructured":"Chisolm JJ Jr, Harrison HE. The exposure of children to lead. Pediatrics.\u20081956;18:943\u2013957","DOI":"10.1542\/peds.18.6.943"},{"key":"2021121006511282800_R3","doi-asserted-by":"crossref","unstructured":"Perlstein MA, Attala R. Neurologic sequelae of plumbism in children. Clin Pediatr.\u20081966;5:292\u2013298","DOI":"10.1177\/000992286600500510"},{"key":"2021121006511282800_R4","doi-asserted-by":"crossref","unstructured":"Pirkle JL, Kaufmann RB, Brody DJ, et al. Exposure of the US population to lead, 1991\u20131994. Environ Health Perspect.\u20081998;11:745\u2013750","DOI":"10.1289\/ehp.98106745"},{"key":"2021121006511282800_R5","unstructured":"Centers for Disease Control and Prevention. Blood lead levels in young children\u2014United States and selected states, 1996\u20131999. MMWR Morb Mortal Wkly Rep.\u20082000;49:1133\u20131137"},{"key":"2021121006511282800_R6","doi-asserted-by":"crossref","unstructured":"Lanphear BP, Dietrich KN, Berger O. Prevention of lead toxicity in US children. Ambul Pediatr.\u20082003;3:27\u201336","DOI":"10.1367\/1539-4409(2003)003<0027:POLTIU>2.0.CO;2"},{"key":"2021121006511282800_R7","doi-asserted-by":"crossref","unstructured":"Canfield RL, Henderson CR, Cory-Slechta DA, Cox C, Jusko TA, Lanphear BP. Intellectual impairment in children with blood lead levels below 10 \u03bcg\/dL. N Engl J Med.\u20082003;348:1517\u20131526","DOI":"10.1056\/NEJMoa022848"},{"key":"2021121006511282800_R8","doi-asserted-by":"crossref","unstructured":"Nightingale SL. Succimer (DMSA) approved for severe lead poisoning. JAMA.\u20081991;265:1802","DOI":"10.1001\/jama.1991.03460140028006"},{"key":"2021121006511282800_R9","unstructured":"United States Centers for Disease Control and Prevention. Preventing Lead Poisoning in Young Children: A Statement by the Centers for Disease Control and Prevention, October 1991. 4th rev. Atlanta, GA: Centers for Disease Control and Prevention; 1991"},{"key":"2021121006511282800_R10","doi-asserted-by":"crossref","unstructured":"Graziano JH, LoIacono NJ, Meyer P. Dose response study of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrations. J Pediatr.\u20081988;113:751\u2013757","DOI":"10.1016\/S0022-3476(88)80396-2"},{"key":"2021121006511282800_R11","doi-asserted-by":"crossref","unstructured":"Treatment of Lead-exposed Children Trial Group. The treatment of lead-exposed children (TLC) trial: design and recruitment for a study of the effect of oral chelation on growth and development of children. Paediatr Perinat Epidemiol.\u20081998;12:313\u2013333","DOI":"10.1046\/j.1365-3016.1998.00122.x"},{"key":"2021121006511282800_R12","doi-asserted-by":"crossref","unstructured":"Treatment of Lead-Exposed Children (TLC) Trial Group. Safety and efficacy of succimer in toddlers with blood lead levels of 20\u201344 \u03bcg\/dL. Pediatr Res.\u20082000;48:593\u2013599","DOI":"10.1203\/00006450-200011000-00007"},{"key":"2021121006511282800_R13","doi-asserted-by":"crossref","unstructured":"Rogan WJ, Dietrich KN, Ware JH, et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med.\u20082001;344:1421\u20131426","DOI":"10.1056\/NEJM200105103441902"},{"key":"2021121006511282800_R14","doi-asserted-by":"crossref","unstructured":"Liu X, Dietrich KN, Radcliffe J, et al. Do children with falling blood lead levels have improved cognition?Pediatrics.\u20082002;110:787\u2013791","DOI":"10.1542\/peds.110.4.787"},{"key":"2021121006511282800_R15","doi-asserted-by":"crossref","unstructured":"Ruff HA, Bijur PE, Markowitz M, Ma YC, Rosen JF. Declining blood lead levels and cognitive changes in moderately lead-poisoned children. JAMA.\u20081993;269:1641\u20131646","DOI":"10.1001\/jama.269.13.1641"},{"key":"2021121006511282800_R16","unstructured":"Bayley N. The Bayley Scales of Infant Development-II. San Antonio, TX: The Psychological Corporation; 1993"},{"key":"2021121006511282800_R17","doi-asserted-by":"crossref","unstructured":"Wechsler D. The Wechsler Preschool and Primary Scales of Intelligence\u2013Revised. San Antonio, TX: The Psychological Corporation; 1989","DOI":"10.1037\/t48859-000"},{"key":"2021121006511282800_R18","unstructured":"Korkman M, Kirk U, Kemp S. NEPSY\u2014A Developmental Neuropsychological Assessment. San Antonio, TX: The Psychological Corporation; 1998"},{"key":"2021121006511282800_R19","doi-asserted-by":"crossref","unstructured":"Conners CK. Conners' Rating Scales\u2013Revised. Technical Manual. North Tonawanda, NY: Multi-Health Systems; 1997","DOI":"10.1037\/t81067-000"},{"key":"2021121006511282800_R20","doi-asserted-by":"crossref","unstructured":"Silverstein AM. Two- and four-subtest short forms of the WAIS-R: a closer look at validity and reliability. J Clin Psychol.\u20081985;41:95\u201397","DOI":"10.1002\/1097-4679(198501)41:1<95::AID-JCLP2270410116>3.0.CO;2-V"},{"key":"2021121006511282800_R21","doi-asserted-by":"crossref","unstructured":"Lidsky TI, Schneider JS. Lead neurotoxicity in children: basic mechanisms and clinical correlates. Brain.\u20082003;126:5\u201319","DOI":"10.1093\/brain\/awg014"},{"key":"2021121006511282800_R22","unstructured":"Dietrich KN. Environmental neurotoxicants and psychological development. In: Yeates KO, Ris MD, Taylor HG, eds. Pediatric Neuropsychology: Research, Theory and Practice. New York, NY: Guilford Press; 2000: 206\u2013234"},{"key":"2021121006511282800_R23","unstructured":"Wechsler D. Wechsler Intelligence Scale for Children-III. San Antonio, TX: The Psychological Corporation; 1991"},{"key":"2021121006511282800_R24","unstructured":"Conners CK. Conners' Continuous Performance Test. North Tonawanda, NY: Multi-Health Systems; 1995"},{"key":"2021121006511282800_R25","unstructured":"Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test\u2013Children's Version. San Antonio, TX: The Psychological Corporation; 1994"},{"key":"2021121006511282800_R26","unstructured":"Woodcock RW. Woodcock Language Proficiency Battery\u2013Revised. Itasca, IL: Riverside Publishing; 1991"},{"key":"2021121006511282800_R27","unstructured":"Reynolds CR, Kamphaus RW. Behavior Assessment System for Children. Circle Pines, MN: American Guidance Service; 1992"},{"key":"2021121006511282800_R28","unstructured":"Denckla MB. Revised neurological examination for subtle signs. Psychopharm Bull.\u20081985;24:773\u2013778"},{"key":"2021121006511282800_R29","doi-asserted-by":"crossref","unstructured":"Peterson KE, Salganik M, Campbell C, et al. Effect of succimer on growth of preschool children with moderate blood lead levels. Environ Health Perspect.\u20082004;112:233\u2013237","DOI":"10.1289\/ehp.6331"},{"key":"2021121006511282800_R30","unstructured":"Dean AG, Dean JA, Colombier D, et al. Epi Info Version 6: A Word-Processing Database and Statistics Program for Public Health on IBM-Compatible Microcomputers. Atlanta, GA: Centers for Disease Control and Prevention; 1996"},{"key":"2021121006511282800_R31","doi-asserted-by":"crossref","unstructured":"Jones MM, Basinger MA, Gale GR, Atkins LM, Smith AB, Stone A. Effect of chelate treatments on kidney, bone and brain lead levels of lead-intoxicated mice. Toxicology.\u20081994;89:91\u2013100","DOI":"10.1016\/0300-483X(94)90217-8"},{"key":"2021121006511282800_R32","doi-asserted-by":"crossref","unstructured":"Smith D, Bayer L, Strupp J. Efficacy of succimer chelation for reducing brain Pb levels in a rodent model. Environ Res.\u20081998;78:168\u2013176","DOI":"10.1006\/enrs.1998.3854"},{"key":"2021121006511282800_R33","doi-asserted-by":"crossref","unstructured":"Smith DR, Woolard D, Luck ML, Laughlin NK. Succimer and the reduction of tissue lead in juvenile monkeys. Toxicol Appl Pharmacol.\u20082000;166:230\u2013240","DOI":"10.1006\/taap.2000.8973"},{"key":"2021121006511282800_R34","doi-asserted-by":"crossref","unstructured":"Cremin JD, Luck ML, Laughlin NK, Smith DR. Efficacy of succimer chelation for reducing brain lead in a primate model of human lead exposure. Toxicol Appl Pharmacol.\u20081999;161:283\u2013293","DOI":"10.1006\/taap.1999.8807"},{"key":"2021121006511282800_R35","doi-asserted-by":"crossref","unstructured":"Welsh MC, Pennington BF. Assessing frontal lobe functioning in children: views from developmental psychology. Dev Neuropsychol.\u20081988;4:199\u2013230","DOI":"10.1080\/87565648809540405"},{"key":"2021121006511282800_R36","unstructured":"Denckla MB. A theory and model of executive function: A neuropsychological perspective. In: Lyon GR, Krasnegor NA, eds. Attention, Memory, and Executive Function. Baltimore, MD: Paul H. Brookes Publishing Co; 1996:263\u2013278"},{"key":"2021121006511282800_R37","doi-asserted-by":"crossref","unstructured":"Anderson V. Assessing executive functions in children: biological, psychological, and developmental considerations. Neuropsychol Rehabil.\u20081998;8:319\u2013349","DOI":"10.1080\/713755568"},{"key":"2021121006511282800_R38","unstructured":"United States Centers for Disease Control and Prevention. Managing Elevated Blood Lead Levels Among Young Children: Recommendations From the Advisory Committee on Childhood Lead Poisoning Prevention, March, 2002. Atlanta, GA: Centers for Disease Control and Prevention; 2002"},{"key":"2021121006511282800_R39","doi-asserted-by":"crossref","unstructured":"Lanphear BP. The paradox of lead poisoning prevention. Science.\u20081998;281:1617\u20131618","DOI":"10.1126\/science.281.5383.1617"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/1\/19\/1006075\/zpe00704000019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/1\/19\/1006075\/zpe00704000019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T15:50:18Z","timestamp":1639151418000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/114\/1\/19\/64789\/Effect-of-Chelation-Therapy-on-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,1]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2004,7,1]]},"published-print":{"date-parts":[[2004,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.114.1.19","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,1]]}}}